A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Clinical trial NCT02643303 · COMPLETED

Trial details

NCT number: NCT02643303
Sponsor: Ludwig Institute for Cancer Research
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma Breast Cancer Sarcoma Merkel Cell Carcinoma Cutaneous T-Cell Lymphoma Melanoma Renal Cancer Bladder Cancer Prostate Cancer Testicular Cancer Solid Tumor

Start date: 2016-12-28
Primary completion: 2022-02-23
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.